FactCheck.org Challenges Ex-HHS Adviser's Claims About Moderna Vaccine

Share

Former HHS adviser Calley Means misrepresented clinical trial findings and FDA's review of Moderna's recently approved mRNA influenza vaccine, according to an 11/20 FactCheck.org analysis. FactCheck.org challenged Means' claims about the vaccine during a recent appearance on The Joe Rogan Experience.”

The analysis follows Means' allegations that former FDA commissioner nominee Heidi Overton pressured former commissioner Marty Makary over the vaccine's approval. In an 11/8 CBS News interview, Means claimed he witnessed Overton conditioning assistance on other policy matters on Makary's willingness to approve the product despite his scientific objections.

Means also claimed that Moderna's mFlusiva was ineffective, caused serious side effects and had been rejected by FDA over safety concerns.

FactCheck.org reported that a randomized trial involving 40,703 participants found approximately 27% fewer laboratory-confirmed influenza cases among recipients of mFlusiva than among those receiving a standard-dose flu vaccine. Although the absolute difference in influenza incidence was approximately 0.8 percentage points, the analysis noted that the comparator was an existing effective vaccine, not placebo.

FDA approved mFlusiva in August for adults 50 and older, granting traditional approval for ages 50–64 and accelerated approval for adults 65 and older. The latter approval was based on immune response data, with confirmatory clinical efficacy data expected in 2030.

The analysis also examined Means' references to deaths in clinical trials. FDA reviewers identified 23 deaths from unspecified causes among mRNA vaccine recipients compared with nine in the standard-vaccine group, but concluded the findings were unlikely to represent a vaccine-related safety signal. Overall mortality and serious adverse event rates were similar between groups.

The mRNA vaccine produced more common short-term reactions, including injection-site pain, fatigue and headache.

FactCheck.org also disputed Means' characterization of FDA's initial refusal to review Moderna's application. The February decision involved objections to the trial's comparator vaccine, rather than a finding that the product was unsafe. FDA subsequently reversed the decision and completed its review.

The analysis acknowledged that direct clinical efficacy data comparing mFlusiva with enhanced influenza vaccines recommended for older adults remain limited.

Read more